Literature DB >> 33743824

Cooperative treatment effectiveness of ATR and HSP90 inhibition in Ewing's sarcoma cells.

Jürgen Sonnemann1,2,3, Zhao-Qi Wang4,5, Christian Marx4, Marc U Schaarschmidt6,7, Joanna Kirkpatrick4,8, Lisa Marx-Blümel6,7, Melisa Halilovic4, Martin Westermann9, Doerte Hoelzer10,11, Felix B Meyer10, Yibo Geng4,12, Katrin Buder4, Hauke M Schadwinkel6,7, Kanstantsin Siniuk4, Sabine Becker6,7, René Thierbach10, James F Beck6.   

Abstract

INTRODUCTION: Ewing's sarcoma is an aggressive childhood malignancy whose outcome has not substantially improved over the last two decades. In this study, combination treatments of the HSP90 inhibitor AUY922 with either the ATR inhibitor VE821 or the ATM inhibitor KU55933 were investigated for their effectiveness in Ewing's sarcoma cells.
METHODS: Effects were determined in p53 wild-type and p53 null Ewing's sarcoma cell lines by flow cytometric analyses of cell death, mitochondrial depolarization and cell-cycle distribution as well as fluorescence and transmission electron microscopy. They were molecularly characterized by gene and protein expression profiling, and by quantitative whole proteome analysis.
RESULTS: AUY922 alone induced DNA damage, apoptosis and ER stress, while reducing the abundance of DNA repair proteins. The combination of AUY922 with VE821 led to strong apoptosis induction independent of the cellular p53 status, yet based on different molecular mechanisms. p53 wild-type cells activated pro-apoptotic gene transcription and underwent mitochondria-mediated apoptosis, while p53 null cells accumulated higher levels of DNA damage, ER stress and autophagy, eventually leading to apoptosis. Impaired PI3K/AKT/mTOR signaling further contributed to the antineoplastic combination effects of AUY922 and VE821. In contrast, the combination of AUY922 with KU55933 did not produce a cooperative effect.
CONCLUSION: Our study reveals that HSP90 and ATR inhibitor combination treatment may be an effective therapeutic approach for Ewing's sarcoma irrespective of the p53 status.

Entities:  

Keywords:  ATM; ATR; Apoptosis; Endoplasmic reticulum (ER) stress; Ewing's sarcoma; HSP90

Year:  2021        PMID: 33743824      PMCID: PMC7981928          DOI: 10.1186/s13578-021-00571-y

Source DB:  PubMed          Journal:  Cell Biosci        ISSN: 2045-3701            Impact factor:   7.133


  66 in total

1.  Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.

Authors:  Srikanth R Ambati; Eloisi Caldas Lopes; Kohji Kosugi; Ullas Mony; Ahmet Zehir; Smit K Shah; Tony Taldone; Andre L Moreira; Paul A Meyers; Gabriela Chiosis; Malcolm A S Moore
Journal:  Mol Oncol       Date:  2013-12-15       Impact factor: 6.603

Review 2.  Ewing's Sarcoma.

Authors:  Nicolò Riggi; Mario L Suvà; Ivan Stamenkovic
Journal:  N Engl J Med       Date:  2021-01-14       Impact factor: 91.245

3.  The genomic landscape of pediatric Ewing sarcoma.

Authors:  Brian D Crompton; Chip Stewart; Amaro Taylor-Weiner; Gabriela Alexe; Kyle C Kurek; Monica L Calicchio; Adam Kiezun; Scott L Carter; Sachet A Shukla; Swapnil S Mehta; Aaron R Thorner; Carmen de Torres; Cinzia Lavarino; Mariona Suñol; Aaron McKenna; Andrey Sivachenko; Kristian Cibulskis; Michael S Lawrence; Petar Stojanov; Mara Rosenberg; Lauren Ambrogio; Daniel Auclair; Sara Seepo; Brendan Blumenstiel; Matthew DeFelice; Ivan Imaz-Rosshandler; Angela Schwarz-Cruz Y Celis; Miguel N Rivera; Carlos Rodriguez-Galindo; Mark D Fleming; Todd R Golub; Gad Getz; Jaume Mora; Kimberly Stegmaier
Journal:  Cancer Discov       Date:  2014-09-03       Impact factor: 39.397

Review 4.  Ewing sarcoma.

Authors:  Thomas G P Grünewald; Florencia Cidre-Aranaz; Didier Surdez; Eleni M Tomazou; Enrique de Álava; Heinrich Kovar; Poul H Sorensen; Olivier Delattre; Uta Dirksen
Journal:  Nat Rev Dis Primers       Date:  2018-07-05       Impact factor: 52.329

5.  Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations.

Authors:  Franck Tirode; Didier Surdez; Xiaotu Ma; Matthew Parker; Marie Cécile Le Deley; Armita Bahrami; Zhaojie Zhang; Eve Lapouble; Sandrine Grossetête-Lalami; Michael Rusch; Stéphanie Reynaud; Thomas Rio-Frio; Erin Hedlund; Gang Wu; Xiang Chen; Gaelle Pierron; Odile Oberlin; Sakina Zaidi; Gordon Lemmon; Pankaj Gupta; Bhavin Vadodaria; John Easton; Marta Gut; Li Ding; Elaine R Mardis; Richard K Wilson; Sheila Shurtleff; Valérie Laurence; Jean Michon; Perrine Marec-Bérard; Ivo Gut; James Downing; Michael Dyer; Jinghui Zhang; Olivier Delattre
Journal:  Cancer Discov       Date:  2014-09-15       Impact factor: 39.397

Review 6.  Exploiting Replication Stress as a Novel Therapeutic Intervention.

Authors:  Jeffrey C Martin; Tamara J Hoegel; Miranda L Lynch; Anna Woloszynska; Thomas Melendy; Joyce E Ohm
Journal:  Mol Cancer Res       Date:  2020-10-05       Impact factor: 6.333

Review 7.  Ewing sarcoma protein: a key player in human cancer.

Authors:  Maria Paola Paronetto
Journal:  Int J Cell Biol       Date:  2013-09-03

8.  STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.

Authors:  Christine M Heske; Arnulfo Mendoza; Leah D Edessa; Joshua T Baumgart; Sunmin Lee; Jane Trepel; David A Proia; Len Neckers; Lee J Helman
Journal:  Oncotarget       Date:  2016-10-04

9.  Efficacy of ATR inhibitors as single agents in Ewing sarcoma.

Authors:  Maria Nieto-Soler; Isabel Morgado-Palacin; Vanesa Lafarga; Emilio Lecona; Matilde Murga; Elsa Callen; Daniel Azorin; Javier Alonso; Andres J Lopez-Contreras; Andre Nussenzweig; Oscar Fernandez-Capetillo
Journal:  Oncotarget       Date:  2016-09-13

10.  Ewing sarcoma fusion oncogene: At the crossroads of transcription and DNA damage response.

Authors:  Aparna Gorthi; Alexander J R Bishop
Journal:  Mol Cell Oncol       Date:  2018-05-29
View more
  3 in total

1.  Assessment of HDAC Inhibitor-Induced Endoplasmic Reticulum (ER) Stress.

Authors:  Melisa Halilovic; Lisa Marx-Blümel; Christian Marx; Katrin Buder; James F Beck; Jürgen Sonnemann
Journal:  Methods Mol Biol       Date:  2023

Review 2.  Recent Advances in Synergistic Antitumor Effects Exploited from the Inhibition of Ataxia Telangiectasia and RAD3-Related Protein Kinase (ATR).

Authors:  Li-Wei Wang; Songwei Jiang; Ying-Hui Yuan; Jilong Duan; Nian-Dong Mao; Zi Hui; Renren Bai; Tian Xie; Xiang-Yang Ye
Journal:  Molecules       Date:  2022-04-12       Impact factor: 4.927

3.  pncCCND1_B Engages an Inhibitory Protein Network to Downregulate CCND1 Expression upon DNA Damage.

Authors:  Ramona Palombo; Maria Paola Paronetto
Journal:  Cancers (Basel)       Date:  2022-03-17       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.